Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
35
MED Quote, Financials, Valuation and Earnings
Last price:
$16.87
Seasonality move
:
-3.81%
Day range:
$16.73 - $17.47
52-week range:
$16.73 - $70.58
Dividend yield:
0%
P/E ratio:
27.74x
P/S ratio:
0.27x
P/B ratio:
0.89x
Volume:
482.5K
Avg. volume:
230.5K
1-year change:
-74.75%
Market cap:
$185.1M
Revenue:
$1.1B
EPS (TTM):
$0.61
Analysts' Opinion
-
Consensus RatingMedifast has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, Medifast has an estimated downside of -2.48% from its current price of $16.92.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $16.92.
Fair Value
-
According to the consensus of 0 analysts, Medifast has -2.48% downside to fair value with a price target of -- per share.
MED vs. S&P 500
-
Over the past 5 trading days, Medifast has underperformed the S&P 500 by -9.9% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Medifast does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Medifast revenues have been falling on a year-over-year basis for 9 quarters in a row. In the most recent quarter Medifast reported revenues of $140.2M.
Earnings Growth
-
Medifast earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Medifast reported earnings per share of $0.10.
Enterprise value:
15.1M
EV / Invested capital:
0.07x
Price / LTM sales:
0.27x
EV / EBIT:
1.39x
EV / Revenue:
0.02x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.45x
Price / Operating cash flow:
5.47x
Enterprise value / EBITDA:
0.64x
Gross Profit (TTM):
$497.8M
Return On Assets:
2.41%
Net Income Margin (TTM):
1.09%
Return On Equity:
3.6%
Return On Invested Capital:
3.6%
Operating Margin:
1.5%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $1.6B | $1.2B | $674.5M | $235.9M | $140.2M | |
| Gross Profit | $1.2B | $868.1M | $497.8M | $177.4M | $105.7M | |
| Operating Income | $199M | $150.3M | $10.8M | $25.5M | $2.1M | |
| EBITDA | $210M | $163M | $23.7M | $28.9M | $5.3M | |
| Diluted EPS | $13.19 | $10.99 | $0.61 | $2.12 | $0.10 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $217.5M | $301.1M | $229.6M | $224.3M | $225M | |
| Total Assets | $260.8M | $371.4M | $326.4M | $320M | $291.2M | |
| Current Liabilities | $112M | $160.9M | $154.3M | $110.1M | $72.4M | |
| Total Liabilities | $120.8M | $175.1M | $175.8M | $127M | $83.9M | |
| Total Equity | $140M | $196.2M | $150.5M | $193M | $207.3M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $135.4M | $188.9M | $39.9M | $29.9M | $9.1M | |
| Cash From Investing | -$14M | -$59.4M | -$17.8M | -$46.5M | -$1.8M | |
| Cash From Financing | -$206.5M | -$86.2M | -$19.4M | -$18.2M | -$3K | |
| Free Cash Flow | $116.1M | $174.3M | $33.8M | $28.3M | $7.7M | |
MED
Sector
Market Cap
$185.1M
$348.1M
Price % of 52-Week High
23.97%
73.74%
Dividend Yield
0%
0%
Shareholder Yield
0.4%
2.64%
1-Year Price Total Return
-74.75%
-12.75%
Beta (5-Year)
1.172
0.504
Dividend yield:
0%
Annualized payout:
$4.95
Payout ratio:
255.16%
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$18.62
200-day SMA
Sell
Level
$22.81
Bollinger Bands (100)
Sell
Level
17.91 - 19.93
Chaikin Money Flow
Buy
Level
41.3M
20-day SMA
Sell
Level
$19.25
Relative Strength Index (RSI14)
Sell
Level
35.99
ADX Line
Sell
Level
13.78
Williams %R
Buy
Level
-96.381
50-day SMA
Sell
Level
$18.72
MACD (12, 26)
Sell
Level
-0.29
25-day Aroon Oscillator
Sell
Level
-28
On Balance Volume
Sell
Level
-11.5M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (10.1573)
Buy
CA Score
(Annual)
Level (3.0208)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Buy
Ohlson Score
Level (-3.2483)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Medifast Inc is a United states based company that produces, distributes and sells products concerning weight loss, weight management, and healthy living. The company generates its revenue from point of sale transactions executed over an e-commerce platform for weight loss, weight management, and other consumable health and nutritional products.
Stock Forecast FAQ
In the current month, MED has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MED average analyst price target in the past 3 months is --.
-
Where Will Medifast Stock Be In 1 Year?
According to analysts, the consensus estimate is that Medifast share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Medifast?
Analysts are divided on their view about Medifast share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Medifast is a Sell and believe this share price will rise from its current level to --.
-
What Is Medifast's Price Target?
The price target for Medifast over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MED A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Medifast is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MED?
You can purchase shares of Medifast via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Medifast shares.
-
What Is The Medifast Share Price Today?
Medifast was last trading at $16.87 per share. This represents the most recent stock quote for Medifast. Yesterday, Medifast closed at $16.92 per share.
-
How To Buy Medifast Stock Online?
In order to purchase Medifast stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
